The expression level of GBE1 was associated with prognosis and CD163+ tumor-associated macrophage infiltration in LUAD, suggesting its potential utility as a prognostic biomarker and immune-related therapeutic target for LUAD patients. The gene discussed is CD163; the disease is neoplasm.